65 results about "Available drugs" patented technology

The invention discloses a stem cell exosome patch and its preparation method and application and belongs to the field of tissue engineering. The stem cell exosome patch comprises the following steps: stem cell is cultured and stem cell exosome is collected; a patch scaffold is prepared; and the exosome obtained is attached to the patch scaffold to prepare the stem cell exosome patch. the stem cell exosome patch obtained has natural and easily available drug sources; action site accuracy of the exosome patch can be guaranteed; effective acting time of the patch after implantation can be prolonged; and potential safety hazard can be avoided to a great extent. Through the method, the stem cell exosome patch with good biological characteristics can be obtained. The invention is a new breakthrough of establishing a biological patch in the field of tissue engineering. Meanwhile, the product also provides a feasible scheme for clinical treatment of diseases. The principle of the invention is scientific and reliable, and the technology is simple and flexible.

The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs. A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient: wherein n represents an integer of 6 to 11

The invention provides a method for advanced treatment of coking wastewater, mainly solving problems existed in the prior technology, such as complex treatment processes, ineffectiveness, and difficulty in meeting a discharging standard. The method is characterized by comprising the following major steps: step one, packing a column, that is, first soaking iron scraps by using a dilute sulfuric acid and a dilute NaOH solution separately, smashing coke, mixing uniformly the iron scraps and the coke with a volume ratio of 10:1, and packing the mixture into an iron-carbon column; step two, carrying out an acidizing treatment on the coking wastewater which has gone through a two-stage biochemical treatment; step three, adding a flocculating agent into the acidized wastewater; step four, carrying out a column chromatography treatment, during which the liquid flows into the iron-carbon column from the bottom portion and flows out from the upper portion; step five, precipitating after carrying out a neutralizing treatment; and step six, repeating operations in step two to step five on supernate obtained in step five. The method for advanced treatment of coking wastewater provided by the invention has the advantages of simple equipment needed in implementation, convenient operation, good effect, quick effectiveness, cheap and easily available drugs and reagents, low cost in operation of the device, and high practicability.

The invention discloses a dropping pill of isatis root and folium isatidis and a preparing method thereof, wherein the preparing method is characterized in that: isatis root and folium isatidis are extracted in a carbon dioxide supercritical extraction method and dried under reduced pressure to generate dried paste, polyethylene glycol 4000 is added and evenly mixed, and liquid paraffin is dropped in so as to prepare the dropping pill of isatis root and folium isatidis. The dropping pill of isatis root and folium isatidis is used for treating grippe, the curative effect is obviously better than commercially-available drugs with the same kind, and better effect is obtained.

The invention relates to hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors, a preparation method thereof and application thereof in preparation of antitumor drugs, andbelongs to the technical field of medicinal chemistry. The compounds have a general formula shown in the specification, wherein 3-position or 4-position monosubstitution is preferred; R2 is preferablyOH, OCH3, F or H; R3 is preferably selected from H and CH2OH; R4 is preferably selected from H, CH3, F, or OCH3; R5 is preferably selected from H, OH, CH2OH, CH3, F and OCH3; X is N or CH; Y is N orCH. The compounds provided by the invention have relatively strong inhibitory activity on LSD1 and HDAC1/6, and have very good selectivity on LSD1, and the in vitro antitumor activity of the multiplecompounds on human colon cancer HCT-116 cell strains and human gastric cancer MGC-803 cell strains is superior to that of commercially available drug SAHA. A basis is provided for research and development of LSD1/HDACs double-target inhibitor drugs, and the compounds can be used as candidates for further development or lead compounds for development of antitumor treatment drugs.

The invention belongs to a Chinese patent medicine and a preparation method thereof, and in particular to a swelling and pain relieving powder for parotitis and a preparation method. The invention mainly solves the technical problems of currently available drugs for the treatment of parotitis, such as long course of treatment, slow swelling relief and easy recurrence. A technical scheme adopted by the invention is as below: the swelling and pain relieving powder for parotitis is prepared from the following raw materials by weight: 8-11 parts of rhubarb, 7-13 parts of fructus evodiae, 9-12 parts of lumbricus, 4-6 parts of Coptis chinensis, 5-8 parts of Arisaema cum bile, 4-7 parts of stiff silkworm and 9-11 parts of Caulis Polygoni Multiflori. The preparation method of the swelling and pain relieving powder for parotitis is as below: first, weighing raw materials according to the above weight; and then evenly mixing the raw materials and grinding the raw materials in a mill into a 300 mesh fine powder.

The invention provides urate oxidase modified by polyethylene glycol. At least 11 of the following amino acid sites in the urate oxidase have PEG modifications: T1, K3, K4, K30, K35, K76, K79, K97, K112, K116, K120, K152, K179, K222, K231, K266, K272, K285, K291 and K293. Compared with similar drugs appearing on the market, at least 11 sites of the amino acid sites in the polyethylene glycol modified urate oxidase have PEG modifications, so that the in-vivo stability of the urate oxidase can be greatly improved and the immunogenicity is reduced under the premise of ensuring the enzyme activityto the maximum extent. The in-vivo drug effect after intramuscular injection can reach the equivalent in-vivo drug effect after intravenous injection of commercially available drugs.

The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have reduced cardiotoxicity. As such, the novel compounds of the invention offer an advantage over currently available drugs. The present invention further relates to methods for preparing the novel Aloe-Emodin Glycoside (AEG) based derivatives, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.

An aminoadamantane nitrate compound represented by formula (I) or a pharmaceutically acceptable salt thereof is disclosed for use in preparing a drug for preventing and/or treating lung diseases. Theaminoadamantane nitrate compound represented by the formula (I) or pharmaceutically acceptable salts thereof can both inhibit NMDA receptor over-activation by non-competitive binding to NMDA receptorchannels and inhibit NMDA receptor over-activation by non-competitive binding, Play anti-inflammatory and antioxidant role, but also targeted pulmonary vascular NMDA receptor release of nitric oxide,dilate pulmonary blood vessels, improve pulmonary circulation and reduce pulmonary hypertension. As such, these compounds can be used as drug for that prevention and/or treatment of lung diseases, including acute lung injury, asthma and chronic obstructive pulmonary disease, and can be combined with existing drugs to form various dosage forms with available drug carriers.

The invention discloses a formula and a production technology of a bone impediment pain-eliminating pill. The pill comprises the following 19 drugs: Rhizoma cibotii, Rhizoma Drynariae, eupolyphaga, safflower, Malaytea Scurfpea Fruit, fried eucommia ulmoides, teasel, salted west fennel, Sichuan fructus chaenomelis, Cyathula officinalis, Radix Aconiti Preparata, prepared Kusnezoff Monkshood Roots, Rhizoma Wenyujin Concisum, radix clematidis, kudzuvine roots, gentiana macrophylla, prepared licorice roots, large centipede, and caulis spatholobi. With the efficacy of tonifying the liver and kidney, strengthening tendons and bones, promoting blood circulation, warming meridians, and dredging collaterals to eliminate impediments, the pill is suitable for neck pains, shoulder pains, fingers numbness, waist pain related lower limber pains, activity limitation, intolerance of chilliness, cold limbs and other symptoms caused by lumbar diseases and cervical spondylosis. The pill has the advantages of easily available drug raw materials, low price, simple preparation, convenient administration, unique curative effect and no toxic and side effect, thus being a drug worth popularizing.

The invention relates to traditional Chinese medicine eye drops for treating trachoma. Trachoma is a chronic infectious ophthalmology disease, and symptoms of the trachoma include rough and uneven appearances which are formed on palpebral conjunctiva surfaces and similar to sand grains in form, so the disease is named 'trachoma'. The trachoma is mainly caused by bad eye health habits such as rubbing of eyes with unwashed hands. Available drugs for treating the trachoma not only are high in cost and manufacturing cost, but also can not effect a radical cure, so that itchy symptoms are always brought to patients, once patients feel itchy and rub eyes with hands, eyes are easy to infect again. Characteristics such as photophobia and lachrymation result in that medicines for oral administration can not achieve therapeutic effects easily in the process of treatment.

The invention discloses an application of tiratrocol to treatment of coxsackie virus infection. The invention provides an application of the tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof or substances taking tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof as active ingredients in any one of the following aspects: inhibiting coxsackie virus, treating diseases caused by coxsackie virus infection, and improving the symptoms caused by coxsackie virus infection. Based on a coxsackie virus drug screening model, an anti-coxsackie virusactive drug namely tiratrocol is screened from commercially available drugs. The tiratrocol has important clinical application value for treating diseases infected with the coxsackie virus.

The invention relates to a gliclazide sustained-release tablet which specifically comprises gliclazide, a skeleton material, a diluent and a pore-foaming agent, and the skeleton material is methacrylic acid copolymer. The gliclazide sustained release tablet provided by the invention has relatively stable dissolution and release properties, does not have a burst release phenomenon, and has a dissolution curve consistent with that of commercially available drugs; meanwhile, the gliclazide sustained release tablet disclosed by the invention has better quality stability, simple preparation process, low production cost and is suitable for industrial large-scale production.

The invention relates to a substance structure optimization guidance method and system based on a structure and pharmacokinetic properties. Ten important properties in chemical synthetic drug analysisare selected, the most similar molecular structure in research and development of commercially available drugs is matched for a compounds according to two factors of properties and structure, and anoptimization process from the molecular structure to a patent medicine is provided to guide structure optimization of new drug compound molecules. By means of the substance structure optimization guidance method and system based on the structure and pharmacokinetic properties, the most similar molecular structure in research and development of commercially available drugs can be matched for the compounds, thereby helping drug research and development personnel compare basic information of the compounds.

The invention discloses a polycyclic benzodifuran compound with a formula (I), a preparation method thereof and an application of the polycyclic benzodifuran compound as an anti-respiratory syncytialvirus (RSV) drug. The polycyclic benzodifuran compound disclosed by the invention has a relatively strong inhibiting effect on respiratory syncytial virus, and the activity of the polycyclic benzodifuran compound is superior to that of the existing commercially available drug ribavirin. Therefore, the compound has a good application prospect in treating related diseases caused by respiratory syncytial virus infection.

The invention discloses a synthetic method for vitamin D2 derivatives. The synthesis of the key intermediate C-24 hydroxyl group for the commercially-available drugs tacalcitol and calcipotriol is basically prepared by using a NaBH4 reduction method. The NaBH4 reduction method has the disadvantages that target product yield is about 50% and the byproduct C-24 hydroxyl epimer alcohol has no value in use. According to the invention, a byproduct 1 or a byproduct 4 respectively produced in preparation of tacalcitol or calcipotriol is used as a starting material, a Dess-Martin reagent is used as an oxidation reagent, and a reaction is carried out in an organic solvent at 0 DEG C to 100 DEG C; after the reaction is completed, cooling to room temperature is carried out and then treatment is carried out so as to obtain an intermediate 2 or 5, respectively; and after treatment, the intermediate 2 or 5 is subjected to a reduction reaction so as to obtain a compound 3 or 6, respectively. Compared with the prior art, the synthetic method provided by the invention has the advantages that raw materials are easily available; reaction conditions are mild; post-treatment is simple; the utilization rate of atoms is increased; and pollution is reduced.

The invention discloses a new use of nifedipine, or medically acceptable salts, esters and solvates of nifedipine in preparation of drugs for preventing and/or treating nicotine addiction, and belongsto the field of pharmaceutical technology. The use of taking nifedipine as drugs for preventing and/or treating nicotine addiction has the following advantages: (1) nifedipine can prevent nicotine addiction, accelerate a withdrawal process and prevent relapse, and the effect is obvious; (2) drug resistance on nifedipine in the aspect of preventing and treating nicotine addiction is avoided; (3) nifedipine is a clinically available drug, so that in research of drugs for preventing and/or treating nicotine addiction, cost of pre-clinical research can be greatly reduced, resources are saved, andthe research cycle can be shortened; and (4) nifedipine with working solutions is free of toxicity during animal experiments.

The invention provides a bionic silk fibroin-based self-driven electrically-controlled drug-loaded patch. The bionic silk fibroin-based self-driven electrically-controlled drug-loaded patch comprises a bionic silk fibroin-based friction nano-generator and a drug-loaded microneedle patch connected with the bionic silk fibroin-based friction nano-generator. The invention further provides a preparation method of the self-driven electric control medicine carrying patch. According to the self-driven electronic control medicine carrying patch, the conversion efficiency of converting biological mechanical energy into electric energy and the sensitivity of sensing response are improved, the friction nanometer generator has the self-cleaning function and is environmentally friendly, meanwhile, the medicine delivery efficiency is improved, and the application prospect is wide. And the electrically-controlled drug-loading patch is not limited by the drug-loading capacity, so that the range of the molecular weight of the available drug is widened, and the limitation of preparation conditions when only depending on the drug-loading microneedle array patch is reduced.